Cargando…

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

To enhance the therapeutic index of T-cell engagers (TCEs), we engineered masked, precision-activated TCEs (XPAT proteins), targeting a tumor antigen (human epidermal growth factor receptor 2 (HER2) or epidermal growth factor receptor (EGFR)) and CD3. Unstructured XTEN polypeptide masks flank the N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cattaruzza, Fiore, Nazeer, Ayesha, To, Milton, Hammond, Mikhail, Koski, Caitlin, Liu, Lucas Y., Pete Yeung, V., Rennerfeldt, Deena A., Henkensiefken, Angela, Fox, Michael, Lam, Sharon, Morrissey, Kari M., Lange, Zachary, Podust, Vladimir N., Derynck, Mika K., Irving, Bryan A., Schellenberger, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132983/ https://www.ncbi.nlm.nih.gov/pubmed/36997747 http://dx.doi.org/10.1038/s43018-023-00536-9

Ejemplares similares

The Radiolabeled HER3 Targeting Molecules for Tumor Imaging
por: Molavipordanjani, Sajjad, et al.
Publicado: (2021)

Targeted delivery of doxorubicin to HER2 positive tumor models
por: Gomari, Hosna, et al.
Publicado: (2019)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Publicado: (2019)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

Lymphatic Vessels as Targets of Tumor Therapy?
por: Karpanen, Terhi, et al.
Publicado: (2001)

Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy
por: Biri-Kovács, Beáta, et al.
Publicado: (2020)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery
por: Geng, Lingling, et al.
Publicado: (2016)

Targeting the tumor vasculature to enhance T cell activity
por: Lanitis, Evripidis, et al.
Publicado: (2015)

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations
por: Fischer, Marcus M., et al.
Publicado: (2017)

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics
por: Sims, Jessica D., et al.
Publicado: (2017)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Emergent heterogeneity in putative mesenchymal stem cell colonies: Single-cell time lapsed analysis
por: Rennerfeldt, Deena A., et al.
Publicado: (2019)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
por: Harris, Faye R., et al.
Publicado: (2018)

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model
por: Rosenthal, Ken S., et al.
Publicado: (2017)

Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
por: Choi, Jun Yong, et al.
Publicado: (2014)

Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice
por: Xenaki, Katerina T, et al.
Publicado: (2021)

Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2+ Cancer Stem Cells
por: Wang, Su He, et al.
Publicado: (2013)

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells
por: Ringhieri, Paola, et al.
Publicado: (2017)

The Effect of the Targeted Recombinant Toxin DARPin-PE40 on the Dynamics of HER2-Positive Tumor Growth
por: Sokolova, E.A., et al.
Publicado: (2017)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics
por: Cavallaro, Palmira Alessia, et al.
Publicado: (2023)

Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
por: Su, Chia-Yu, et al.
Publicado: (2018)

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
por: DeFazio-Eli, Lisa, et al.
Publicado: (2011)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
por: Wang, Lei, et al.
Publicado: (2020)

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
por: Gu, Chang-ling, et al.
Publicado: (2021)

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2
por: Balbuena-Rebolledo, Irving, et al.
Publicado: (2021)

Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies
por: Koopaei, Mona Noori, et al.
Publicado: (2011)

Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
por: Bragado, Paloma, et al.
Publicado: (2020)

DARPin_9-29-Targeted Gold Nanorods Selectively Suppress HER2-Positive Tumor Growth in Mice
por: Proshkina, Galina M., et al.
Publicado: (2021)

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma
por: Pastorino, Fabio, et al.
Publicado: (2013)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Blocking Gi/o-Coupled Signaling Eradicates Cancer Stem Cells and Sensitizes Breast Tumors to HER2-Targeted Therapies to Inhibit Tumor Relapse
por: Lyu, Cancan, et al.
Publicado: (2022)

Pharmacological Targeting of the Pseudokinase Her3
por: Xie, Ting, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jhnui28noiqvhqfonsd7b9eeqi